Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
The clinical significance of intraductal carcinoma of the prostate (IDC‐P) in men with nonmetastatic prostate cancer (PCa) treated with high‐dose external‐beam radiation therapy remains unclear. The aim of this study was to evaluate the impact of IDC‐P in men who received intensity‐modulated radiati...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277254/ https://www.ncbi.nlm.nih.gov/pubmed/35514196 http://dx.doi.org/10.1111/cas.15392 |
_version_ | 1784745916815638528 |
---|---|
author | Aizawa, Rihito Tsuzuki, Toyonori Haga, Hironori Nakamura, Kiyonao Ogata, Takashi Inoue, Takahiro Kobayashi, Takashi Akamatsu, Shusuke Goto, Takayuki Ogawa, Osamu Mizowaki, Takashi |
author_facet | Aizawa, Rihito Tsuzuki, Toyonori Haga, Hironori Nakamura, Kiyonao Ogata, Takashi Inoue, Takahiro Kobayashi, Takashi Akamatsu, Shusuke Goto, Takayuki Ogawa, Osamu Mizowaki, Takashi |
author_sort | Aizawa, Rihito |
collection | PubMed |
description | The clinical significance of intraductal carcinoma of the prostate (IDC‐P) in men with nonmetastatic prostate cancer (PCa) treated with high‐dose external‐beam radiation therapy remains unclear. The aim of this study was to evaluate the impact of IDC‐P in men who received intensity‐modulated radiation therapy (IMRT) for nonmetastatic PCa. All patients with high‐risk (H‐R) and very high–risk (VH‐R) PCa who received IMRT between September 2000 and December 2013 at our institution were analyzed retrospectively. We re‐reviewed biopsy cores for the presence of IDC‐P. Treatment consisted of IMRT (median: 78 Gy at 2 Gy per fraction) plus 6‐month neoadjuvant hormonal therapy (HT). In total, 154 consecutive patients with H‐R and VH‐R PCa were analyzed. Intraductal carcinoma of the prostate was present in 27.9% (n = 43). The median follow‐up period was 8.4 years. The 10‐year PCa‐specific survival, biochemical failure (BF), clinical failure, and castration‐resistant PCa rates were 90.0%, 47.8%, 27.5%, and 24.5% in patients with IDC‐P, and 96.6%, 32.6%, 10.8%, and 7.0% in those without IDC‐P, respectively (p = 0.12, 0.04, 0.0031, and 0.012, respectively). In multivariable analysis, IDC‐P was not identified as an independent predictive factor for BF (p = 0.26). The presence of IDC‐P was correlated with a significantly higher incidence of disease progression in men with H‐R and VH‐R PCa who received IMRT, although it was not identified as an independent predictive factor for BF. Further investigations are needed to determine the significance of IDC‐P as an independent predictive factor for survival outcomes. |
format | Online Article Text |
id | pubmed-9277254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92772542022-07-15 Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy Aizawa, Rihito Tsuzuki, Toyonori Haga, Hironori Nakamura, Kiyonao Ogata, Takashi Inoue, Takahiro Kobayashi, Takashi Akamatsu, Shusuke Goto, Takayuki Ogawa, Osamu Mizowaki, Takashi Cancer Sci ORIGINAL ARTICLES The clinical significance of intraductal carcinoma of the prostate (IDC‐P) in men with nonmetastatic prostate cancer (PCa) treated with high‐dose external‐beam radiation therapy remains unclear. The aim of this study was to evaluate the impact of IDC‐P in men who received intensity‐modulated radiation therapy (IMRT) for nonmetastatic PCa. All patients with high‐risk (H‐R) and very high–risk (VH‐R) PCa who received IMRT between September 2000 and December 2013 at our institution were analyzed retrospectively. We re‐reviewed biopsy cores for the presence of IDC‐P. Treatment consisted of IMRT (median: 78 Gy at 2 Gy per fraction) plus 6‐month neoadjuvant hormonal therapy (HT). In total, 154 consecutive patients with H‐R and VH‐R PCa were analyzed. Intraductal carcinoma of the prostate was present in 27.9% (n = 43). The median follow‐up period was 8.4 years. The 10‐year PCa‐specific survival, biochemical failure (BF), clinical failure, and castration‐resistant PCa rates were 90.0%, 47.8%, 27.5%, and 24.5% in patients with IDC‐P, and 96.6%, 32.6%, 10.8%, and 7.0% in those without IDC‐P, respectively (p = 0.12, 0.04, 0.0031, and 0.012, respectively). In multivariable analysis, IDC‐P was not identified as an independent predictive factor for BF (p = 0.26). The presence of IDC‐P was correlated with a significantly higher incidence of disease progression in men with H‐R and VH‐R PCa who received IMRT, although it was not identified as an independent predictive factor for BF. Further investigations are needed to determine the significance of IDC‐P as an independent predictive factor for survival outcomes. John Wiley and Sons Inc. 2022-05-19 2022-07 /pmc/articles/PMC9277254/ /pubmed/35514196 http://dx.doi.org/10.1111/cas.15392 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | ORIGINAL ARTICLES Aizawa, Rihito Tsuzuki, Toyonori Haga, Hironori Nakamura, Kiyonao Ogata, Takashi Inoue, Takahiro Kobayashi, Takashi Akamatsu, Shusuke Goto, Takayuki Ogawa, Osamu Mizowaki, Takashi Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy |
title | Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy |
title_full | Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy |
title_fullStr | Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy |
title_full_unstemmed | Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy |
title_short | Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy |
title_sort | clinical significance of idc‐p as predictive factor after intensity‐modulated radiation therapy |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277254/ https://www.ncbi.nlm.nih.gov/pubmed/35514196 http://dx.doi.org/10.1111/cas.15392 |
work_keys_str_mv | AT aizawarihito clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT tsuzukitoyonori clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT hagahironori clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT nakamurakiyonao clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT ogatatakashi clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT inouetakahiro clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT kobayashitakashi clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT akamatsushusuke clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT gototakayuki clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT ogawaosamu clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy AT mizowakitakashi clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy |